Table 1.
Baseline characteristics from the phase 2a and 2b studies
| FINLAY-FR-1A vaccine group (n=364)* | Vaccine excipient group (n=86) | ||
|---|---|---|---|
| Sex | |||
| Female | 204 (56%) | 47 (55%) | |
| Male | 160 (44%) | 39 (45%) | |
| Race | |||
| White | 224 (62%) | 55 (64%) | |
| Black | 54 (15%) | 11 (13%) | |
| Mixed race | 85 (23%) | 20 (23%) | |
| East Asian | 1 (<1%) | 0 | |
| Age, years | |||
| Mean (SD) | 46·0 (14·3) | 45·0 (14·3) | |
| Median (IQR) | 49·0 (24·0) | 45·0 (23·0) | |
| Range | 19–78 | 21–78 | |
| 19–59 years age group | 305 (84%) | 77 (90%) | |
| 60–78 years age group | 59 (16%) | 9 (10%) | |
| Weight, kg | |||
| Mean (SD) | 74·5 (15·0) | 73·7 (14·6) | |
| Median (IQR) | 74·0 (21·0) | 73·0 (21·1) | |
| Range | 44·0–130·0 | 44·0–105·0 | |
| Height, cm | |||
| Mean (SD) | 166·0 (9·0) | 165·6 (10·0) | |
| Median (IQR) | 165·0 (12·0) | 166·0 (1·3) | |
| Range | 147–198 | 145–190 | |
| Body-mass index, kg/m2 | |||
| Mean (SD) | 26·9 (4·3) | 26·8 (4·2) | |
| Median (IQR) | 27·0 (6·5) | 27·0 (6·4) | |
| Range | 18·4–35·3 | 18·3–34·7 | |
| Time from hospital discharge with negativeCOVID-19 PCR test to vaccination, months | |||
| Mean (SD) | 4·5 (3·3) | 4·8 (3·9) | |
| Median (IQR) | 3·1 (1·3) | 3·0 (1·4) | |
| Range | 1·8–15·9 | 2·0–15·5 | |
| COVID-19 classification | |||
| Asymptomatic | 85 (23%) | 25 (29%) | |
| Mild | 245 (67%) | 38 (44%) | |
| Moderate | 34 (9%) | 23 (27%) | |
Data are n (%) unless stated otherwise.
*
n=364 comprises 20 participants from the phase 2a study and 344 participants from the phase 2b study.